Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK in lung cancer: past, present, and future.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2013

Shaw Alice T, Engelman Jeffrey A

Abstract excerpt

In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positive cancers are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. Phase I and II studies of crizotinib in ALK-positive lung cancer demonstrated impressive activity and clinical benefit, leading to rapid US Food and Drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Clinical Trials as Topic
Share to Crizotinib

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gene Rearrangement

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23401436
DOI: 10.1200/JCO.2012.44.5353
PMCID: PMC4209068

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK in lung cancer: past, present, and future.PMID 23401436Read ↗

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.Semantic proximity Read ↗

ALK alterations and inhibition in lung cancer.Semantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.Semantic proximity Read ↗

ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancerSemantic proximity Read ↗

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.Semantic proximity Read ↗

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Semantic proximity Read ↗

Targeting Anaplastic Lymphoma Kinase in Lung CancerSemantic proximity Read ↗

Unraveling the Potential of ALK-Targeted Therapies in NSCLC: Comprehensive Insights and Future DirectionsSemantic proximity Read ↗

ALK‐ rearrangement in non‐small‐cell lung cancer (NSCLC)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.